Viral Infections in Dialysis Patients Part A: Human Immunodeficiency Virus Infection in Dialysis Patients

  • T. K. Sreepada Rao


Some of the important questions for nephrologists providing maintenance hemodialysis (MH) or peritoneal dialysis (PD) to patients with end stage renal disease (ESRD) who are also infected with various viral agents include:
  1. a)

    What is the preferential mode of renal replacement therapy for ESRD patients, if the long-term prognosis is determined by the nature and severity of viral infection?

  2. b)

    What are the different therapeutic strategies to treat these infected patients, such as the deployment of antiviral drugs, immunomodulators, and others, and their adverse effects in patients with compromised renal function?

  3. c)

    What are the combined effects of superimposition of immunosuppression on chronic uremia, maintenance dialysis, renal transplantation, and immunosuppressive therapy, on the natural history of viral disease, especially in patients infected with the human immunodeficiency virus (HIV) which preferentially affects the T cell system?



Peritoneal Dialysis Continuous Ambulatory Peritoneal Dialysis Chronic Uremia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 36 (No 1S): 3S, 1987Google Scholar
  2. 2. 1993 revised classification system for HIV infection and expanded case definition for AIDS among adolescents and adults. MMWR 41 (No RR-17): 1, 1992Google Scholar
  3. 3.
    Rao TKS, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, Friedman EA: Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310: 669, 1984PubMedCrossRefGoogle Scholar
  4. 4.
    Gardenswartz MH, Lerner CW, Seligson GR et al.: Renal disease in patients with AIDS: a clinicopathologic study. Clin Nephrol 21: 197, 1984PubMedGoogle Scholar
  5. 5.
    Pardo V, Aldana M, Colton RM et al.: Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 101: 429, 1984PubMedGoogle Scholar
  6. 6.
    Rao TKS, Friedman EA, Nicastri AD: The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 316: 1062, 1987PubMedCrossRefGoogle Scholar
  7. 7.
    Rao TKS, Friedman EA: AIDS (HIV) associated nephropathy: does it exist? An in-depth review. Am J Nephrol 9: 441, 1989PubMedGoogle Scholar
  8. 8.
    Rao TKS, Friedman EA: Outcome of severe acute renal failure in patients with the acquired immunodeficiency syndrome. In pressGoogle Scholar
  9. 9.
    Rao TKS, Berns JS: Acute renal failure in patients with HIV infection. in Renal and urologic aspects of HIV infection, edited by Kimmel PL, Berns JS, New York, Churchill Livingstone. In pressGoogle Scholar
  10. 10.
    Bourgoignie JJ, Meneses R, Ortiz C, Jaffe D, Pardo V: The clinical spectrum of renal disease associated with human immunodeficiency virus. Am J Kidney Dis 12: 131, 1988PubMedGoogle Scholar
  11. 11.
    Chander P, Soni A, Suri A, Bhagwat R, Yoo J, Treser G: Renal ultrastructural markers in AIDS-associated nephropathy. Am J Pathol 126: 513, 1987PubMedGoogle Scholar
  12. 12.
    Chander P, Agarwal A, Soni A, Kim K, Treser G: Renal cytomembranous inclusions in idiopathic renal disease as predictive markers for the acquired immunodeficiency syndrome. Hum Pathol 19: 1060, 1988PubMedCrossRefGoogle Scholar
  13. 13.
    Cohen AH, Sun NCJ, Shapshak P, Imagawa DT: Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Modern Pathol 2: 125, 1989Google Scholar
  14. 14.
    Kopp JB, Klotman ME, Adler SH et al.: Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 89: 1577, 1992PubMedCrossRefGoogle Scholar
  15. 15.
    Kopp JB, Bruggeman LA, Klotman PE: Extracellular matrix gene expression in experimental glomerulonephritis. Curr Opinions Nephrol Hypertension 2: 609, 1993CrossRefGoogle Scholar
  16. 16.
    Shukla RR, Kumar A, Kimmel PL: Transforming growth factor beta increases the expression of HIV-1 gene in transfected human mesangial cells. Kidney Int 44: 1022, 1993PubMedCrossRefGoogle Scholar
  17. 17.
    United States Renal Data System: 1993 annual data report, p 24Google Scholar
  18. 18.
    ESRD Network of New York: 1992 annual report. July 1993Google Scholar
  19. 19.
    Tokras JI, Alter MJ, Favero MS, Moyer LA, Bland LA: National Surveillance of dialysis-associated diseases in the United States, 1992. ASAIO J. In pressGoogle Scholar
  20. 20.
    Rao TKS: Acquired immunodeficiency syndrome human immunodeficiency virus and dialysis. in: International Yearbook of Nephrology 1991, edited by Andreucci VE, Fine LG, Boston, MA, Kluwer Academic publishers, 1990, p 199Google Scholar
  21. 21.
    Rao TKS: Maintenance dialysis in patients with human immunodeficiency virus infection. Semin Dial 1: 203, 1988CrossRefGoogle Scholar
  22. 22.
    Ortiz C, Meneses R, Jaffe JA Fernandez JA, Perez G, Bourgoignie JJ: Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 34: 248, 1988PubMedCrossRefGoogle Scholar
  23. 23.
    Ribot S, Dean D, Goldblat M, Saavedra M: Prognosis of HIV positive dialysis patients. Kidney Int 37: 315, 1990Google Scholar
  24. 24.
    Feinfeld DA, Kaplan R, Dressler R, Lynn I: Survival of human immunodeficiency virus-infected patients on maintenance dialysis. Clin Nephrol 32: 221, 1989PubMedGoogle Scholar
  25. 25.
    Chirgwin K, Rao TKS, Landesman SH: HIV infection in a high prevalence hemodialysis unit. AIDS 3: 731, 1989PubMedGoogle Scholar
  26. 26.
    Kimmel PL, Umana WO, Simmens SJ, Watson J, Bosch JP: Continuous ambulatory peritoneal dialysis and survival of HIV infected patients with end-stage renal disease. Kidney Int 44: 373, 1993PubMedCrossRefGoogle Scholar
  27. 27.
    Tebben JA, Rigsby MO, Selwyn PA, Brennan N, Kliger A, Finkelstein FO: Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int 44: 191, 1993PubMedCrossRefGoogle Scholar
  28. 28.
    Campbell J, Markowitz N, Fisher EJ, Cruz C: Continuous ambulatory peritoneal dialysis for the AIDS patient. in Ambulatory Peritoneal dialysis, edited by Avram MM, Giordano C, New York, Plenum Publishing Co, 1990, p 266Google Scholar
  29. 29.
    Diskin CJ: AIDS-related complex by continuous ambulatory peritoneal dialysis. Nephron 51: 548, 1989PubMedGoogle Scholar
  30. 30.
    Rubin J: Prevalence of HIV virus among patients undergoing continuous ambulatory peritoneal dialysis. Trans Am Soc Artif Intern Organs 35: 144, 1989Google Scholar
  31. 31.
    Baumgartner DD, Arterbery VE, Hale AJ, Gupta RK, Bradley SF: Peritoneal dialysis-associated tuberculous peritonitis in an intravenous drug user with acquired immunodeficiency syndrome. Am J Kidney Dis 14(2): 154, 1989PubMedGoogle Scholar
  32. 32.
    Dressler R, Peters AT, Lynn RI: Pseudomonal and candidal peritonitis as a complication of continuous ambulatory peritoneal dialysis in human immunodeficiency virusinfected patients. Am J Med 86: 787, 1989PubMedCrossRefGoogle Scholar
  33. 33.
    Elsey RM, Carson RW, Dubose TD Jr: Pasteurella multocida peritonitis in an HIV-positive patient on continuous cycling peritoneal dialysis. Am J Nephrol 11: 61, 1991PubMedGoogle Scholar
  34. 34.
    Lewis M, Gorban-Brennan NL, Kliger A, Cooper K, Finkelstein FO: Incidence and spectrum of organisms causing peritonitis in HIV positive patients on CAPD. Adv Perit Dial 6: 136, 1990PubMedGoogle Scholar
  35. 35.
    Wasser WG, Boyle MJ, Brandon S, Gruber SJ, Winston RV, Feldman NS: HIV positivity does not predispose peritoneal dialysis patients to peritonitis. J Am Soc Nephrol 2: 369, 1991Google Scholar
  36. 36.
    Correa-Rotter R, Saldivar S, Soto LE, de Leon PS, Pena JC: Recovery of HIV antigen in peritoneal dialysis fluid. Perit Dial Int 10: 67, 1990PubMedGoogle Scholar
  37. 37.
    Breyer JA, Harbison MA: Isolation of human immunodeficiency virus from peritoneal dialysate. Am J Kidney Dis 21: 23, 1993PubMedGoogle Scholar
  38. 38.
    Shrivastava D, Delano BG, Lundin P, Rao TKS, Markell M, Friedman EA: Factors affecting survival of HIV+ patients undergoing maintenance hemodialysis. J Am Soc Nephrol 3: 320, 1992CrossRefGoogle Scholar
  39. 39.
    Blum MR, Liao SHT, Good SS, Miranda PD: Pharmacokinetics and bioavailability of Zidovudine in humans. Am J Med 85(Suppl 2A): 189, 1988PubMedGoogle Scholar
  40. 40.
    Gleason JR Jr, Brier ME: Zidovudine in renal failure. Semin Dial 3: 101, 1990CrossRefGoogle Scholar
  41. 41.
    Paoli I, Dave M, Cohen BD: Pharmacodynamics of zidovudine in patients with end stage renal disease. N Engl J Med 326: 839, 1992PubMedCrossRefGoogle Scholar
  42. 42.
    Kremer D, Munar MY, Kohlgepp SJ et al.: Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. Pharmacotherapy 12: 56, 1992PubMedGoogle Scholar
  43. 43.
    Spivak JL, Barnes DC, Fuchs E, Quinn TC: Serum immunoreactive erythropoietin in HIV-infected patients. JAAM 261: 3104, 1989CrossRefGoogle Scholar
  44. 44.
    Shrivastava D, Rao TKS, Sinert R, Khurana E, Lundin AP, Friedman EA: The efficacy of erythropoietin in HIV infected end stage renal disease patients treated by maintenance hemodialysis. In pressGoogle Scholar
  45. 45.
    Berns JS, Cohen RM, Rudnick MR, Bennett WM: Renal aspects of antimicrobial therapy for HIV infection. in Renal and urologic aspects of HIV infection, edited by Kimmel PL, Berns JS, New York, Churchill Livingstone. In pressGoogle Scholar
  46. 46.
    Descamps-Latscha B, Herbelin A: Long-term dialysis and cellular immunity: a critical survey. Kidney Int 43(Suppl 41): S135, 1993Google Scholar
  47. 47.
    Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha B: Immune deficiency of the uremic patient. Adv Nephrol 19: 259, 1990Google Scholar
  48. 48.
    Van Noesel: Functional and phenotypic evidence for selective loss of memory T cells in asymptomatic HIV infected men. J Clin Invest 86: 293, 1990PubMedCrossRefGoogle Scholar
  49. 49.
    Pinching AJ: Antibody responses in HIV infection. Clin Exp Immunol 84: 181, 1989Google Scholar
  50. 50.
    Goldfeld AE, Birch-Limberger K, Schooley RT, Walker BD: HIV-1 infection does not induce tumor necrosis factor-alpha or interferon-beta gene transcription. J Acquir Immune Defic Syndr 4: 41, 1991PubMedGoogle Scholar
  51. 51.
    Munis JR, Richman DD, Kombluth RS: Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF)/cachectin gene expression nor alters TNF/cachectin induction by lipopolysaccharide. J Clin Invest 85: 591, 1990PubMedGoogle Scholar
  52. 52.
    Edelbaum DE: No AIDS among patients on dialysis? N Engl J Med 314: 187, 1986PubMedGoogle Scholar
  53. 53.
    Alter MJ, Favero MS, Moyer LA, Miller JK, Bland LA. National Surveillance of dialysis-associated diseases in the United States, 1988. ASAIO Trans 36: 107, 1990PubMedCrossRefGoogle Scholar
  54. 54. Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodbome pathogens in health-care settings. MMWR 37: 377, 1988Google Scholar
  55. 55. Guidelines for for prevention of transmission of human immunodeficiency virus and hepatitis B virus to healthcare and public safety workers. MMWR 38 (S-6): 1, 1989Google Scholar
  56. 56. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. MMWR 40 (RR-8): 1, 1991Google Scholar
  57. 57.
    Martin LS, McDougal SJ, Loskoski SL: Disinfection and inactivation of Human T Lymphotropic virus type III/Lymphadenopathy-associated virus. J Infect Dis 152: 39, 1985Google Scholar
  58. 58.
    Shapshak P, McCoy CB, Rivers JE et ai: Inactivation of human immunodeficiency virus-1 at short time intervals using undiluted bleach. J Acqd Immune Def Synd 6: 218, 1993Google Scholar
  59. 59.
    Reiser I, Shapiro W, Porush J: The incidence and epidemiology of human immunodeficiency virus infection in 320 patients treated in an inner city hemodialysis center. Am J Kidney Dis 16: 26, 1990PubMedGoogle Scholar
  60. 60.
    Perez GO, Ortiz C, De Medina M, Schiff E, Bourgoignie JJ: Lack of transmission of human immunodeficiency virus in chronic hemodialysis patients. Am J Nephrol 8: 123Google Scholar
  61. 61.
    Assogba U, Park A, Rey MA, Barthelemy A, Rottembourg J, Gluckman JC: Prospective study of HIV 1 seropositive patients in hemodialysis centers. Clin Nephrol 29: 312, 1988PubMedGoogle Scholar
  62. 62.
    Marcus R, Favero MS, Banerjee S et al.: Prevalence and incidence of human immunodeficiency virus among patients undergoing long-term hemodialysis. Am J Med 90:614, 1991PubMedGoogle Scholar
  63. 63.
    Berlyne G, Kaczmarek RG, Hamburger S et al.: Seroprevalence of antibodies to the human immunodeficiency virus in dialysis workers: results of a multi-center study. Nephron 62: 441, 1992PubMedGoogle Scholar
  64. 64.
    Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH Jr: Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 13: 537, 1991PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • T. K. Sreepada Rao
    • 1
  1. 1.SUNY Health Science Center at BrooklynBrooklynUSA

Personalised recommendations